Protein stabilization improves STAT3 function in autosomal dominant hyper-IgE syndrome

Blood

Volumn 128, Issue 26, 2016, Pages 3061-3072

  Bocchini, Claire E ^a   Nahmod, Karen ^a   Katsonis, Panagiotis ^a   Kim, Sang ^b   Kasembeli, Moses M ^b   Freeman, Alexandra ^c   Lichtarge, Olivier ^a   Makedonas, George ^a   Tweardy, David J ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK TRANSCRIPTION FACTOR 1; HEAT SHOCK TRANSCRIPTION FACTOR 1A; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 6; MESSENGER RNA; STAT3 PROTEIN; TEPRENONE; TYROSINE; UNCLASSIFIED DRUG; CYTOKINE; DITERPENE; DNA BINDING PROTEIN; HEAT SHOCK TRANSCRIPTION FACTOR; MUTANT PROTEIN; PHOSPHOTYROSINE; PROTEIN BINDING; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPARATIVE STUDY; COMPUTER MODEL; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN CELL; HYPER IGE SYNDROME; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MISFOLDING; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN STRUCTURE; SPLEEN CELL; T LYMPHOCYTE; TH17 CELL; UPREGULATION; ANIMAL; CHEMISTRY; DRUG EFFECTS; GENETICS; HALF LIFE TIME; IMMUNOLOGY; METABOLISM; MOLECULAR MODEL; MUTATION; PATHOLOGY; PHYSIOLOGY; SPLEEN;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DITERPENES; DNA-BINDING PROTEINS; HALF-LIFE; HERPESVIRUS 4, HUMAN; HUMANS; INTERLEUKIN-17; JOB SYNDROME; MICE; MODELS, MOLECULAR; MUTANT PROTEINS; MUTATION; PHOSPHOTYROSINE; PROTEIN BINDING; PROTEIN STABILITY; SPLEEN; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS;

EID: 85015009905     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-02-702373     Document Type: Article

References (52)

1. Davis SD, Schaller J, Wedgwood RJ. Job's Syndrome. Recurrent, "cold", staphylococcal abscesses. Lancet. 1966;1(7445):1013-1015.
2. Holland SM, DeLeo FR, Elloumi HZ, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med. 2007;357(16):1608-1619.
3. Jiao H, Tóth B, Erdos M, et al. Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients from different ethnic groups. Mol Immunol. 2008;46(1):202-206.
4. Minegishi Y, Saito M, Tsuchiya S, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 2007;448(7157):1058-1062.
5. Freeman AF, Avila EM, Shaw PA, et al. Coronary artery abnormalities in Hyper-IgE syndrome. J Clin Immunol. 2011;31(3):338-345.
6. Renner ED, Rylaarsdam S, Anover-Sombke S, et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H) 17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol. 2008;122(1):181-187.
7. Woellner C, Gertz EM, Schäffer AA, et al. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin Immunol. 2010;125(2):424-432.e8.
8. Gennery AR, Flood TJ, Abinun M, Cant AJ. Bone marrow transplantation does not correct the hyper IgE syndrome. Bone Marrow Transplant. 2000;25(12):1303-1305.
9. Kimata H. High-dose intravenous gamma-globulin treatment for hyperimmunoglobulinemia E syndrome. J Allergy Clin Immunol. 1995;95(3):771-774.
10. Patel NC, Gallagher JL, Torgerson TR, Gilman AL. Successful haploidentical donor hematopoietic stem cell transplant and restoration of STAT3 function in an adolescent with autosomal dominant hyper-IgE syndrome. J Clin Immunol. 2015;35(5):479-485.
11. Steward-Tharp SM, Laurence A, Kanno Y, et al. A mouse model of HIES reveals pro- and anti-inflammatory functions of STAT3. Blood. 2014;123(19):2978-2987.
12. Sato N, Yamamoto T, Sekine Y, et al. Involvement of heat-shock protein 90 in the interleukin-6-mediated signaling pathway through STAT3. Biochem Biophys Res Commun. 2003;300(4):847-852.
13. Novak U, Ji H, Kanagasundaram V, Simpson R, Paradiso L. STAT3 forms stable homodimers in the presence of divalent cations prior to activation. Biochem Biophys Res Commun. 1998;247(3):558-563.
14. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3(9):651-662.
15. Ghoshal S, Rao I, Earp JC, Jusko WJ, Wetzler M. Down-regulation of heat shock protein 70 improves arsenic trioxide and 17-DMAG effects on constitutive signal transducer and activator of transcription 3 activity. Cancer Chemother Pharmacol. 2010;66(4):681-689.
16. Kasembeli M, Lau WC, Roh SH, et al. Modulation of STAT3 folding and function by TRiC/CCT chaperonin. PLoS Biol. 2014;12(4):e1001844.
17. Dehouck Y, Kwasigroch JM, Gilis D, Rooman M. PoPMuSiC 2.1: a web server for the estimation of protein stability changes upon mutation and sequence optimality. BMC Bioinformatics. 2011;12:151.
18. Capriotti E, Fariselli P, Casadio R I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure. Nucleic Acids Res. 2005;33(Web Server issue):W306-W310.
19. Zhou H, Zhou Y. Distance-scaled, finite ideal-gas reference state improves structure-derived potentials of mean force for structure selection and stability prediction. Protein Sci. 2002;11(11):2714-2726.
20. Worth CL, Preissner R, Blundell TL. SDM - a server for predicting effects of mutations on protein stability and malfunction. Nucleic Acids Res. 2011;39(Web Server issue):W215-W222.
21. Cheng J, Randall A, Baldi P. Prediction of protein stability changes for single-site mutations using support vector machines. Proteins. 2006;62(4):1125-1132.
22. Mihalek I, Res I, Lichtarge O. A family of evolution-entropy hybrid methods for ranking protein residues by importance. J Mol Biol. 2004;336(5):1265-1282.
23. Beckler GS, Thompson D, Van Oosbree T. In vitro translation using rabbit reticulocyte lysate. Methods Mol Biol. 1995;37:215-232.
24. Mizuno F, Aya T, Osato T. Growth in semisolid agar medium of human cord leukocytes freshly transformed by Epstein-Barr virus. J Natl Cancer Inst. 1976;56(1):171-173.
25. Cherney BW, Bhatia K, Tosato G. A role for deregulated c-Myc expression in apoptosis of Epstein-Barr virus-immortalized B cells. Proc Natl Acad Sci USA. 1994;91(26):12967-12971.
26. Franch HA, Sooparb S, Du J, Brown NS. A mechanism regulating proteolysis of specific proteins during renal tubular cell growth. J Biol Chem. 2001;276(22):19126-19131.
27. Bharadwaj U, Eckols TK, Kolosov M, et al. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer. Oncogene. 2015;34(11):1341-1353.
28. Neef DW, Turski ML, Thiele DJ. Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease. PLoS Biol. 2010;8(1):e1000291.
29. McAllister F, Bailey JM, Alsina J, et al. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell. 2014;25(5):621-637.
30. Schimke LF, Sawalle-Belohradsky J, Roesler J, et al. Diagnostic approach to the hyper-IgE syndromes: immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis. J Allergy Clin Immunol. 2010;126(3):611-617, e611.
31. Freeman AF, Renner ED, Henderson C, et al. Lung parenchyma surgery in autosomal dominant hyper-IgE syndrome. J Clin Immunol. 2013;33(5):896-902.
32. Papanastasiou AD, Mantagos S, Papanastasiou DA, Zarkadis IK. A novel mutation in the signal transducer and activator of transcription 3 (STAT3) gene, in hyper-IgE syndrome. Mol Immunol. 2010;47(7-8):1629-1634.
33. Heimall J, Davis J, Shaw PA, et al. Paucity of genotype-phenotype correlations in STAT3 mutation positive Hyper IgE Syndrome (HIES). Clin Immunol. 2011;139(1):75-84.
34. Powers AE, Bender JM, Kumánovics A, et al. Coccidioides immitis meningitis in a patient with hyperimmunoglobulin E syndrome due to a novel mutation in signal transducer and activator of transcription. Pediatr Infect Dis J. 2009;28(7):664-666.
35. Ma CS, Chew GYJ, Simpson N, et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med. 2008;205(7):1551-1557.
36. Avery DT, Deenick EK, Ma CS, et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med. 2010;207(1):155-171.
37. Kim HJ, Kim JH, Shin YK, Lee SI, Ahn KM. A novel mutation in the linker domain of the signal transducer and activator of transcription 3 gene, p.Lys531Glu, in hyper-IgE syndrome. J Allergy Clin Immunol. 2009;123(4):956-958.
38. van de Veerdonk FL, Marijnissen R, Joosten LAB, et al. Milder clinical hyperimmunoglobulin E syndrome phenotype is associated with partial interleukin-17 deficiency. Clin Exp Immunol. 2010;159(1):57-64.
39. Wilkins A, Erdin S, Lua R, Lichtarge O. Evolutionary trace for prediction and redesign of protein functional sites. Methods Mol Biol. 2012;819:29-42.
40. BeckerS, GronerB, Müller CW. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature. 1998;394(6689):145-151.
41. He J, Shi J, Xu X, et al. STAT3 mutations correlated with hyper-IgE syndrome lead to blockage of IL-6/STAT3 signalling pathway. J Biosci. 2012;37(2):243-257.
42. Sinn D-I, Chu K, Lee S-T, et al. Pharmacological induction of heat shock protein exerts neuroprotective effects in experimental intracerebral hemorrhage. Brain Res. 2007;1135(1):167-176.
43. Mohr A, Fahrenkamp D, Rinis N, Müller-Newen G. Dominant-negative activity of the STAT3-Y705F mutant depends on the N-terminal domain. Cell Commun Signal. 2013;11:83.
44. Price BA, Sandoval IM, Chan F, et al. Rhodopsin gene expression determines rod outer segment size and rod cell resistance to a dominant-negative neurodegeneration mutant. PLoS One. 2012;7(11):e49889.
45. Chandesris MO, Melki I, Natividad A, et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine (Baltimore). 2012;91(4):e1-e19.
46. Yanagimachi M, Ohya T, Yokosuka T, et al. The Potential and Limits of Hematopoietic Stem Cell Transplantation for the Treatment of Autosomal Dominant Hyper-IgE Syndrome. J Clin Immunol. 2016;36(5):511-516.
47. Dong G, Chen Z, Kato T, Van Waes C. The host environment promotes the constitutive activation of nuclear factor-kappaB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. Cancer Res. 1999;59(14):3495-3504.
48. Yadav SPS, Chanda R, Gathwala G, Yadav RK. Actinomycosis of tonsil masquerading as tumour in a 12-year old child. Int J Pediatr Otorhinolaryngol. 2002;63(1):73-75.
49. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798-809.
50. Sampaio EP, Bax HI, Hsu AP, et al. A novel STAT1 mutation associated with disseminated mycobacterial disease. J Clin Immunol. 2012;32(4):681-689.
51. Tsumura M, Okada S, Sakai H, et al. Dominant-negative STAT1 SH2 domain mutations in unrelated patients with Mendelian susceptibility to mycobacterial disease. Hum Mutat. 2012;33(9):1377-1387.
52. Varco-Merth B, Feigerlová E, Shinde U, Rosenfeld RG, Hwa V, Rotwein P. Severe growth deficiency is associated with STAT5b mutations that disrupt protein folding and activity. Mol Endocrinol. 2013;27(1):150-161.